PRAX-114 is an extrasynaptic-preferring GABAA receptor positive allosteric modulator
in development for treatment of major depressive disorder (MDD). Extrasynaptic preference
was hypothesized to explain preclinical findings demonstrating >20-fold separation
between antidepressant- and sedative-like doses in rodents, and the lack of dose-limiting
sedation in a Phase 1 trial assessing PRAX-114 safety and tolerability in healthy
participants. Here we report results from an open-label Phase 2 trial assessing safety,
tolerability and preliminary efficacy in MDD.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
